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Abstract
Background: Pre-eclampsia and Eclampsia are relatively common complications of pregnancy, leading to
considerable maternal and fetal mortality and morbidity. We sought to review the effect of aspirin, calcium
supplementation, antihypertensive agents and magnesium sulphate on risk stillbirths.
Methods: A systematic literature search was conducted to identify studies evaluating the above interventions. We
used a standardized abstraction and grading format and performed meta-analyses where data were available from
more than one studies. The estimated effect on stillbirths was determined by applying the standard Child Health
Epidemiology Reference Group (CHERG) rules for multiple outcomes. For interventions with insufficient evidence
for overall effect, a Delphi process was undertaken to estimate effectiveness.
Results: We identified 82 relevant studies. For aspirin, maganesium sulphate and use of antihypertensive we found
an insignificant decrease in stillbirth and perinatal mortality. For calcium supplementation, there was a borderline
significant reduction in stillbirths (RR 0.81, 95 % CI 0.63-1.03). We undertook a Delphi consultation among experts
to assess the potential impact of a package of interventions for the management of pre-eclampsia and eclampsia
(antihypertensive, magnesium sulphate and C-section if needed). The Delphi process suggested 20% reduction
each in both antepartum and intrapartum stillbirths with the use of this package.
Conclusions: Despite promising benefits of calcium supplementation and aspirin use cases on maternal morbidity
and eclampsia in high risk cases, further work is needed to ascertain their benefits in relation to stillbirths. The
Delphi process undertaken for assessing potential impact of a package of interventions indicated that this could be
associated with 20% reduction in stillbirths, for input into LiST.
Background
Hypertensive disease of pregnancy (HDP) is one of the
most common complications of pregnancy, occurring in
5-8% of the pregnancies [1]. Hypertensive disorders are
the second most common cause of maternal deaths
worldwide [2]. There are several major categories of
hypertensive disorders in pregnancy ranging from mild
to moderate rise in blood pressure without proteinuria
[usually called pregnancy induced hypertension (PIH)],
preeclampsia (hypertension with proteinuria), severe
preeclampsia and eclampsia [3]. Maternal hypertension,
even of the mild to moderate category, can lead to
adverse perinatal outcomes like low birth weight, pre-
maturity, stillbirth and intrauterine growth retardation
[4]. A population-based study of 57 million singleton
live- and stillbirths has shown that pregnancy induced
hypertension (PIH) is associated with increased risk of
stillbirth and neonatal mortality [5]. The risk of stillbirth
was higher in women having their second or higher
order births [(Odds Ratio (OR) =2.24, 95% confidence
interval (CI) =2.11-2.37)] compared with women having
their first birth (OR=1.52, 95% CI=1.40-1.64).
Detection and prevention of maternal hypertensive dis-
orders is important in order to avoid morbidity and mor-
tality associated with them [6]. Potential interventions for
reducing the risk of preeclampsia include calcium and
aspirin used for prevention and use of anti-hypertensive
drugs and magnesium sulphate for management of
preeclampsia/eclampsia. A 17% reduction in the risk of
preeclampsia was noted with the use of antiplatelet
agents – mostly low dose aspirin - in pregnant women
at risk of preeclampsia (RR 0.83 95% CI 0.77-0.89) [7].
A Cochrane review [8] that included 13 randomized trials
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plementation during pregnancy reduces the incidence of
preeclampsia by 55 % [Relative risk (RR) =0.45 95 % con-
fidence interval (CI) 0.31-0.65] and that of gestational
hypertension by 35 % [RR=0.65, 95 % CI 0.53-0.81]. The
reduction in the risk of preeclampsia was greatest for
women at high risk of developing preeclampsia (RR 0.22,
95% CI 0.12-0.42), and for those with low baseline intake
of calcium (RR 0.36, 95% CI 0.20-0.65). A variety of anti-
hypertensive agents including beta-blockers like labetalol
[9,10], atenolol [11,12], oxeprenolol [13]; calcium-channel
blockers like isradipine [14], nifedipine [15,16]; and other
antihypertensive drugs like methyldopa (an alpha-blocker)
[17-19] have been shown to be effective in controlling
blood pressure during pregnancy. Magnesium sulphate
(MgSO4) supplementation has been shown to be effective
for prevention of eclampsia in pre-eclamptic women [20].
A Cochrane review [21] that included six trials for
MgSO4 analysis has shown that compared with placebo
or no anticonvulsant, MgSO4 reduced the risk of eclamp-
sia by 59 % [RR 0.41, 95% CI 0.29 to 0.58].
The purpose of this paper was to review the effect of
calcium supplementation, aspirin, antihypertensive
agents, and magnesium sulphate on stillbirths and peri-
natal mortality related to maternal hypertensive disor-
ders. This paper is a part of series of papers for the Lives
Saved Tool (LiST). The process of generating a point
estimate for efficacy of an intervention involves qualita-
tive evaluation of available evidence according to Grading
of Recommendations, Assessment, Development and
Evaluation (GRADE) criteria [22] and quantitative mea-
sure according to Child Health Epidemiology Reference
Group (CHERG) rules [23]. For more details of the
review methods, the adapted GRADE approach or the
LiST model see the methods paper [23] and other articles
in this supplement.
Methods
We systematically reviewed all published literature from
1957 to June 2010 to identify studies that reported the
effect of calcium supplements, aspirin, antihypertensive
drugs or magnesium sulphate on stillbirths and perinatal
mortality as outcomes amongst pregnant women. As per
CHERG guidelines [23], we searched PubMed, the
Cochrane Library and all WHO regional databases and
included publications available in any language [23].
Two search strategies were used as follows:
1) (aspirin OR antiplatelet OR antihypertensive* OR
“beta-blocker*” OR “calcium channel blocker*” OR
“alpha-blocker*” OR “magnesium sulphate”) AND (preg-
nancy or maternal) AND (stillbirth* OR “perinatal mor-
tality” OR “fetal death*” OR eclampsia OR “severe
preeclampsia” OR “intrauterine death” OR “preeclamp-
sia” OR” preeclampsia*).
2) “Calcium” AND “pregnancy” AND (“Hypertension”
OR “preeclampsia” OR “blood pressure” OR “Stillbirth”
OR “Intrauterine death”).
Every effort was made to gather unpublished data
when reports were available for full abstraction. Previous
reviews were also hand-searched for relevant studies not
picked up in the primary literature search [3,24-26]
Inclusion/exclusion criteria
We included randomized and quasi-randomized con-
trolled trials that evaluated the following as an interven-
tion: calcium supplements, aspirin with or without other
antiplatelet agents, antihypertensive agents of any cate-
gory, and magnesium sulphate. Studies were included if
they had an identical control group that was given either
placebo or no treatment. The studies were selected irre-
spective of the dose used. For calcium, only those stu-
dies were included in which baseline calcium intake of
participants was low as calcium supplementation during
pregnancy is effective only in population with low cal-
cium intake. We excluded any studies reporting only
before-after comparisons as well as observational studies
and in addition we excluded those studies that did not
report outcomes of interest for this review.
Abstraction, analysis, and summary measures
All studies that met the final inclusion and exclusion
criteria were double-data abstracted into a standardized
form for each outcome. We extracted the data for study
design; location; population; methods; limitations;
assessment of blinding, allocation concealment; and out-
comes of interest. Each study was assessed and graded
according to the CHERG adaptation of the GRADE
technique. Each study was assigned a final quality grade
of “high”“ moderate”“ low” or “very low” on the basis of
strengths and limitations of study [22,23]. Studies
receiving a grade of ‘very low’ were excluded from the
analysis. The grading of overall (pooled) evidence was
based on three components: (1) the volume and consis-
tency of the evidence; (2) the size of the pooled effect
and (3) the strength of the statistical evidence reflected
in the p-value [23]. A similar grading of ‘high’‘ moder-
ate’‘ low’ and ‘very low’ was used for grading the overall
evidence indicating the strength of an effect of the inter-
vention on specific health outcome [23]
We undertook meta-analyses where data were avail-
able from more than one study for an outcome and
reported Mantel-Haenszel pooled relative risks and
corresponding 95 % confidence intervals. The primary
outcome of interest was stillbirth. Statistical heteroge-
neity in the pooled data was assessed by visual inspec-
tion of overlap of confidence intervals and P-value
(P < 0.10 was taken to mean substantial heterogeneity).
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pooled analysis was done by visual inspection i.e. the
overlap of the confidence intervals among the studies,
Chi square (P-value) of heterogeneity in the meta-ana-
lyses and I
2 statistics. A low P value (less than 0.10) or
a large chi-squared statistics relative to its degree of
freedom and I
2 values greater than 50% were taken as
substantial and high heterogeneity. In situations of
substantial or high heterogeneity being present, causes
were explored by sensitivity analysis and random
effects model were used.
Results
We identified 2069 titles from the first search strategy
and 1022 titles from the second, in searches conducted
in databases including PubMed and the Cochrane
Library (Figure 1). After initial screening of these titles
and abstracts, we reviewed 121 papers to identify out-
comes of interest and included 82 papers in the final
database. All the included studies were blinded, rando-
mized, controlled treatment trials. The detailed data
extraction with the limitation of studies is shown in
Additional File 1. In tables 1, 2, 3, 4, we report the
quality assessment of studies of each intervention by
outcome, as well as results from corresponding
meta-analyses.
Aspirin in high-risk pregnancy
To estimate the effect of aspirin in high-risk pregnancies
for prevention of preeclampsia, we found 21 studies
which reported data on the effect of aspirin alone on still-
births [1,4,9,12,13,15-19,27-37] and 3 studies reporting
combined effects of aspirin and diypyramidole on still-
births [38-40]. A total of 13 studies reported perinatal
mortality [1,4,15,17,27,29,31,33,35,36,39,41-43] (Table 1).
The effect of aspirin alone showed no significant effect
on risk of stillbirths (RR= 1.15; 95% CI: 0.88 to 1.49)
(Figure 2). Combining studies of aspirin with dipyrami-
dole with aspirin alone yielded similar results (RR= 1.06;
95% CI: 0.82 to 1.37).
Calcium supplementation in low-intake population
To estimate the effect of calcium supplementation in
pregnant women in low-intake population, we found
3 studies which reported data on stillbirths, [55-57]
and 4 studies which reported perinatal mortality
(Table 2). Our analysis suggested that calcium sup-
plementation during pregnancy could potentially
reduce stillbirths by 19%, however results were not
statistically significant (RR 0.81, 95 % CI 0.63-1.03)
(Figure 3). These data suggest the need for further
large scale studies of calcium supplementation in
populations with specific assessment of stillbirth
outcomes.
Antihypertensive agents in pregnancy with mild to
moderate hypertension
To estimate the effect of antihypertensive agents in
pregnant women with mild to moderate hypertension,
we found 18 studies which reported data on stillbirths
[10,14,58-73] and twenty studies which reported data on
perinatal mortality [14,58,60,61,63-66,68,69,71-80]
(Table 3).The effect of antihypertensive drugs showed
no effect for stillbirths (RR= 1.14; 95% CI: 0.60 to 2.17)
(Figure 4).
Magnesium sulphate in pregnancy with preeclampsia
To estimate the effect of magnesium sulphate for preg-
nancies with preeclampsia versus placebo or no treat-
ment, we found 3 studies which reported data on
stillbirths [82-84], 2 studies which reported perinatal
mortality [82,83] (Table 4). There was no impact of use
of magnesium sulphate on stillbirths (RR= 0.99; 95% CI:
0.87 to 1.12) (Figure 5).
Delphi process for establishing expert consensus
As there was no convincing evidence in favor or against
of use of antihypertensive and magnesium sulphate with
respect to stillbirths, we sought expert consensus via the
Delphi method [23]. The panel invited to participate
were experts belonging to six WHO regions (South Asia,
Africa, Western Europe, Eastern Europe, North America,
and Australia) and a range of disciplines including mater-
nal health, public health, obstetrics/gynecology, and mid-
wifery. 33 experts agreed to participate in the Delphi
process. The questionnaire was developed by MYY and
ZAB, and refined after several rounds of pilot testing.
The questionnaire was sent by email and included the
background and aims of the Delphi and estimates of
effect that were available from the literature for different
scenarios. The median response and range were deter-
mined for each question. Consensus was defined a priori
as an interquartile range in responses of not more than
30% for each question and in this instance; consensus
was achieved after first iteration. The Delphi consensus
suggested median effect of 20% reduction in antepartum
and intrapartum stillbirths with the HDP package with
interquartile ranges of 10-30% and 10-40% respectively
(Figure 6).
Discussion
Over 2.5 million babies are born dead each year, making
stillbirth one of the most important adverse outcomes
of pregnancy [88]. Hypertension during pregnancy is a
risk factor for stillbirth [89-91] especially in low socioe-
conomic settings [92]. The two most commonly used
preventive measures are; use of aspirin in high risk preg-
nancies and calcium supplementation in populations
with low calcium intake [20]. In this review we have
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Table 1 Quality assessment of trials of aspirin alone in high-risk pregnancies for prevention of preeclampsia
Quality Assessment Summary of Findings
Directness No of events
No of
studies
(ref)
Design Limitations Consistency Generalizability
to population
of interest
Generalizability
to intervention
of interest
Intervention Control Relative Risk
(95% CI)
Stillbirths: LOW outcome specific quality
21 RCT High non-compliance
rate, Small sample size,
Placebo not used, Not
double-blinded.
Consistent; Low
heterogeneity
(p=0.62); Results
statistically
insignificant
1 study in
developing
country
Yes 113 95 1.15 (0.88, 1.49)
Perinatal mortality: MODERATE/LOW outcome specific quality
13 RCT Low compliance; Small
sample size
Consistent; Low
heterogeneity
(p=0.39); Results
statistically
insignificant
3 studies in
developing
countries
Yes 187 209 0.89 (0.74, 1.08)
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decrease in stillbirths (RR= 1.15; 95% CI: 0.88 to 1.49).
Results of this review are different from that of
Cochrane review [25] on the topic (aspirin) as data for
stillbirth were pooled with miscarriages in the Cochrane
review. The combined results in the Cochrane review
also showed no effect of aspirin (RR=0.96; CI= 0.78 to
1.18]. In any case, despite having a protective effect
against pre-eclampsia, there was no convincing evidence
to recommend use of ‘aspirin alone’ for reduction of
stillbirths for input to the Live Saved Tool (LiST).
Analysis in this review has shown that calcium supple-
mentation during pregnancy reduced stillbirths by 19 %;
however results were not statistically significant (RR
0.81, 95 % CI 0.63-1.03). A Cochrane review on effec-
tiveness of calcium supplementation during pregnancy
[24] also showed a statistically insignificant 30% reduc-
tion in the outcome of stillbirths or death before dis-
charge (RR 0.70, 95% CI 0.69 to 1.09). There was
however 55 % reduction in risk of preeclampsia (RR
0.45, 95% CI 0.31 to 0.65). Although the evidence in
support of calcium supplementation for women at risk
of low intake is robust [24], further research is needed
with assessment of the full range of pregnancy outcomes
before this can be recommended for inclusion in the
LiST model for prevention of stillbirth.
This review has shown that use of antihypertensive
drugs has no effect on incidence of stillbirths, which is
similar to the results from the Cochrane review
(RR=1.14 CI=0.60 to 2.17) [3].
I ts h o u l db en o t e dt h a tm o s td a t ai n c l u d e di nt h i s
review for aspirin, antihypertensive agents and magne-
sium sulphate was from developed countries, as data
from developing countries was scarce. Several studies
had too small a sample size to be able to detect differ-
ences in stillbirths. Moreover, noncompliance rates to
the aspirin were as high as 20% in certain studies. In a
few studies, a no-treatment group was used as a control
group instead of a placebo group, which may have
affected the results.
Given these limitations of the data, we also used the
Delphi process to generate an impact estimate for
impact of a package of interventions that involve detec-
tion and management of hypertensive disease of preg-
nancy. The package included use of an appropriate
antihypertensive, magnesium supplementation in case of
Table 2 Quality assessment of studies of calcium supplementation during pregnancy to prevent stillbirths from
maternal hypertensive disorders:
Quality Assessment Directness Summary of findings
No. of
studies
(Ref)
Design Limitations Consistency Generalizability
to Population of
Interest
Generalizability to intervention
of Interest
Events in
intervention
group
Events in
control
group
Relative Risk
(95 % CI)
Stillbirth: Moderate outcome specific quality
3 RCT None Consistent
(I
2 =0)
Yes all from
developing
countries
Dose of calcium supplementation
ranged from 1.5-2 g/day in all the
included studies
117 145 0.81 (0.63-1.03)a
Perinatal mortality: Low outcome specific quality
4 RCTs None Consistent
(I
2 =0)
Yes All from
developing
countries
Dose of calcium supplementation
ranged from 1.5-2 g/day in all the
included studies
154 179 0.86 (0.70-1.07)a
Table 3 Quality assessment of trials of antihypertensive agents in pregnancies with mild to moderate hypertension
Quality Assessment Summary of Findings
Directness No of events
No of
studies
(ref)
Design Limitations Consistency Generalizability
to population of
interest
Generalizability
to intervention
of interest
Intervention Control Relative Risk
(95% CI)
Stillbirths: MODERATE/LOW outcome specific quality
18 RCT Small sample
size, Placebo
not used
Consistent; Low
heterogeneity (p=0.93);
Results statistically
insignificant
3 studies in
developing
countries
Yes 18 16 1.14 (0.60, 2.17)
Perinatal mortality: MODERATE/LOW outcome specific quality
20 RCT Small sample
size, Placebo
not used
Consistent; Low
heterogeneity (p=0.97);
Results statistically
insignificant
3 studies in
developing
countries
Yes 30 82 0.96 (0.60, 1.54)
Jabeen et al. BMC Public Health 2011, 11(Suppl 3):S6
http://www.biomedcentral.com/1471-2458/11/S3/S6
Page 5 of 11Study or Subgroup
1.1.1 Aspirin alone vs. placebo or no treatment
August 1994
Caspi 1994
Dekker 1989
ECPPA 1996
Gallery 1997
Hauth 1993
Italian study 1993
Kincaid-Smith 1996
McParland 1990
Rotchell 1998
Schiff 1989
Schrocksnadel 1992
Sibai 1993
Subtil 2003
Uzan 1991
Vainio 2002
Viinikka 1993
Wallenburg 1986
Wallenburg 1991
Yu 2003
Zimmermann 1997
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 13.19, df = 15 (P = 0.59); I² = 0%
Test for overall effect: Z = 1.02 (P = 0.31)
1.1.2 Aspirin and dipyramidole vs. placebo or no treatment
Azar 1990
Beaufils 1985
Railton 1988
Rogov 1993
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 1.93, df = 2 (P = 0.38); I² = 0%
Test for overall effect: Z = 2.11 (P = 0.03)
Total (95% CI)
Total events
Heterogeneity: Chi² = 18.12, df = 18 (P = 0.45); I² = 1%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
Events
1
0
0
28
4
1
13
0
1
29
0
0
17
9
2
0
1
1
0
6
0
113
0
0
2
0
2
115
Total
24
48
5
482
58
302
634
27
48
1834
34
22
1505
1645
156
43
97
23
17
276
13
7293
46
48
30
31
155
7448
Events
1
2
0
23
0
1
14
0
2
27
0
1
7
8
4
0
0
0
0
4
1
95
0
4
1
4
9
104
Total
25
46
5
503
50
302
538
25
52
1841
32
19
1519
1660
73
43
100
23
18
278
13
7165
45
45
14
33
137
7302
Weight
0.9%
2.3%
20.4%
0.5%
0.9%
13.7%
1.7%
24.4%
1.5%
6.3%
7.2%
4.9%
0.4%
0.5%
3.6%
1.4%
90.6%
4.2%
1.2%
4.0%
9.4%
100.0%
M-H, Fixed, 95% CI
1.04 [0.07, 15.73]
0.19 [0.01, 3.89]
Not estimable
1.27 [0.74, 2.17]
7.78 [0.43, 141.05]
1.00 [0.06, 15.91]
0.79 [0.37, 1.66]
Not estimable
0.54 [0.05, 5.78]
1.08 [0.64, 1.81]
Not estimable
0.29 [0.01, 6.72]
2.45 [1.02, 5.89]
1.14 [0.44, 2.94]
0.23 [0.04, 1.25]
Not estimable
3.09 [0.13, 74.98]
3.00 [0.13, 70.02]
Not estimable
1.51 [0.43, 5.30]
0.33 [0.01, 7.50]
1.15 [0.88, 1.49]
Not estimable
0.10 [0.01, 1.88]
0.93 [0.09, 9.45]
0.12 [0.01, 2.11]
0.22 [0.05, 0.90]
1.06 [0.82, 1.37]
Antiplatelet drugs Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 2 Forest plot for the effect of aspirin on stillbirths.
Table 4 Quality assessment of trials of magnesium sulphate in pregnancies with preeclampsia
Quality Assessment Summary of Findings
Directness No of events
No of
studies
(ref)
Design Limitations Consistency Generalizability
to population of
interest
Generalizability
to intervention
of interest
Intervention Control Relative Risk
(95% CI)
Stillbirths: HIGH/MODERATE outcome specific quality
3 RCT None Consistent; Low
heterogeneity (p=0.34);
Results statistically
insignificant
2 studies in
developing
countries
Yes 424 426 0.99 (0.87, 1.12)
Perinatal mortality: HIGH/MODERATE outcome specific quality
2 RCT None Consistent; Low
heterogeneity (p=0.45);
Results statistically
insignificant
1 study in
developing
country
Yes 538 541 0.98 (0.88, 1.10)
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Page 6 of 11preeclampsia/eclampsia and availability of C-section
when required. The selection of this package was based
on the fact these interventions are accepted standards of
care for management of preeclampsia/eclampsia [6];
however their role in prevention of stillbirths has
not been extensively studied as described above. We
therefore contacted experts in the field (total 33) and
asked their opinion on how effective this package of
intervention could be to reduce incidence of stillbirths.
The results yielded a reduction of 20 % in antepartum
and intrapartum stillbirths. It should be noted that this
evidence is based on expert’s opinion only and consid-
ered as the weakest evidence in the CHERG’sm e t h o d s
of evaluation of effectiveness of an intervention [23]. We
therefore recommend that future research should focus
on better understanding of the role of detection and
Study or Subgroup
Blake 1991
Bott-Kanner 1992
Butters 1990
Cruickshank 1992
Gruppo 1998
Högstedt 1985
Kahhale 1985
Nascimento 2000
Odendaal 1991
Plouin 1990
Redman 1976
Rubin 1983
Sibai 1987
Sibai 1990
Sibai 1992
Walker 1982
Wichman 1984
Wide-Swensson 1995
Total (95% CI)
Total events
Heterogeneity: Chi² = 4.93, df = 11 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.41 (P = 0.68)
Events
2
1
1
0
3
3
2
0
1
2
1
1
0
1
0
0
0
0
18
Total
17
30
15
51
132
86
47
90
12
78
117
60
102
194
99
64
26
54
1274
Events
1
0
0
0
2
1
1
1
3
1
3
2
0
1
0
0
0
0
16
Total
19
30
14
63
129
82
47
94
20
76
125
60
103
98
101
62
26
57
1206
Weight
5.6%
2.9%
3.0%
11.9%
6.0%
5.9%
8.7%
13.3%
6.0%
17.1%
11.8%
7.8%
100.0%
M-H, Fixed, 95% CI
2.24 [0.22, 22.51]
3.00 [0.13, 70.83]
2.81 [0.12, 63.83]
Not estimable
1.47 [0.25, 8.63]
2.86 [0.30, 26.95]
2.00 [0.19, 21.31]
0.35 [0.01, 8.43]
0.56 [0.06, 4.76]
1.95 [0.18, 21.05]
0.36 [0.04, 3.38]
0.50 [0.05, 5.37]
Not estimable
0.51 [0.03, 7.99]
Not estimable
Not estimable
Not estimable
Not estimable
1.14 [0.60, 2.17]
Antihypertensive drugs Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 4 Forest plot for the effect of antihypertensive agents on stillbirths.
Figure 3 Forest plot for the effect of calcium supplementation on stillbirths.
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prevention of stillbirths. It is possible that a package of
interventions has an effect that is greater than the indi-
vidual components and the inclusion of, for example, C
Section, may explain the effect attributed to the package
as a whole by the experts. Finally, it is possible the
experts were unaware of negative summary data of com-
ponents of the package.
Conclusion
In conclusion, aspirin and calcium play a significant role
in prevention of preeclampsia however their role in redu-
cing stillbirths is not well established. Antihypertensive
and magnesium sulphate supplementation for hyperten-
sive disorders in pregnancy reduce morbidity and mortal-
ity associated with these disorders however their role in
reducing stillbirths is not clear. Based on expert’s opinion
a package of detection and management of gestational
hypertensive disorders (Antihypertensive, MgSO4 and C-
Section) was estimated to reduce the incidence of still-
births by 20 %.
Additional material
Additional File 1: Data extraction sheet for studies included in the
review.
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